A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Cenobamate (Primary)
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors SK biopharmaceuticals
- 05 Oct 2023 Planned End Date changed from 1 Oct 2024 to 1 Mar 2025.
- 05 Oct 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Feb 2024.
- 05 Oct 2023 Status changed from recruiting to active, no longer recruiting.